About SPPH
SPPH is a newly founded public company that has its main operations in Pharmaceutical Research and Development.
SPPH has acquired 15 years of extensive research , accelerating our path to commercialization.
SPPH is currently focusing on developing 2 patented applications -
L`Institut National des Sciences Appliques de Rouen (INSA Rouen) has discovered a new technology in the challenging area of drugs delivered to the Central Nervous System through an innovative approach that allows the crossing of the blood-brain barrier and dramatically reducing the side effects of drugs used for neurological diseases.
L`Universite du Qubec Montral (UQAM) has discovered how to control the release of existing therapeutics molecules in order to increase their bio-availability and systemic efficacy.
The past few years, the scientific team of SPPH has been dedicated to prove the concept and has claimed the intellectual property through
a registered patent . The therapeutic challenges being the same for all Central Nervous System (CNS) diseases, INSA has created a series of prodrugs able to cross efficiently the Blood Brain Barrier and outclass all the current commercial drugs for CNS diseases. (Alzheimer`s, depression, Schizophrenia, bipolar disorder and brain tumours).
SPPH is now ready for Clinical trials.
SPPH has forged relationships with two highly respected laboratories located in Universities throughout the world.
Universit du Qubec Montral (UQAM) has discovered and tested a system based on an intelligent vehicle that we believe is the best for oral delivery which can protect a small-molecule, a peptide or a protein during the passage of the gastro-intestinal tract and ensure the uptake of bioactive molecules from the gut into the bloodstream in an active form. In this case, UQUAM`s technology will make it easier and less painful and offer increased convenience, patient compliance, and reduced overall health costs. "We firmly believe that the simplicity and versatility of UQAM`s formulations make this novel natural matrix compatible with various drugs and highly competitive in the field of drug delivery systems." - SPPH
The Alzheimer`s Disease (AD)
In 2006, global sales of the AD drugs were worth some US$ 1.6 billion . The Alzheimer`s drugs are relatively expensive medicines ( costing
around $1,700 to $2,300 per year for the patient ). They can cause side effects however and these outweigh the sometimes limited benefits and lead to the end of the treatment. Thus, a new drug or strategy such as the one that INSA has developed with no side effects and good benefits would be a real advantage to the patient.
My name is Pastor Phil, and I invented Windows 7 :)
AI
